AJPMHS GLOBAL RESEARCH NETWORK

AMERICAN Journal of Pediatric Medicine and Health Sciences
Volume 3, Issue 5, 2025 ISSN (E): 2993-2149

Analysis of Anthelmintic Agents, Indications for Their Use and Disadvantages Associated

Sokhib Rashidov Zamon o'g'li, Zarnigor Salaydinova Norqabulovna, Mukhlisa Solieva Zafar qizi, Nilufar Ergasheva Ag'zamjon qizi, Risolat Saidjonova Umidjon qizi
Department of pharmacology, Tashkent medical academy
rashidovsohib9295@gmail.com

Abstract: Helminths are a group of parasites that are producing serious health issues for animals all over the world. Pharmaceutical anthelmintics have been the mainstay of helminthiasis control. Unfortunately, a significant and striking degree of anthelmintic resistance has resulted from the overuse of anthelmintic medications. A heritable loss of anthelmintic sensitivity in a parasite population that was previously susceptible to the same anthelmintic is known as anthelmintic resistance. Almost all animal species' helminths and various anthelmintic groups across many continents exhibit signs of developing anthelmintic resistance. Anthelmintic resistance is predisposed by the parasite's genetics, underdosing, frequent therapy, and the timing and targeting of mass treatment. The primary mechanisms of anthelmintic resistance include upregulation of cellular efflux mechanisms, increased drug metabolism, altered drug receptor sites that decrease drug binding or the functional effects of drug binding, and decreased drug receptor abundance due to decreased expression within the parasite. Anthelmintic resistance can be found using in vitro techniques like PCR, egg hatch assays, larval mobility tests, and larval development tests, as well as in vivo techniques like the fecal egg count reduction test. The development of anthelmintic resistance can be slowed down by utilizing anthelmintic medications appropriately, combining anthelmintic medications, and using alternate methods. Given that anthelmintic resistance is a major global issue, it is important to use the current anthelmintics appropriately and lessen reliance on them in order to lessen the problem.

Keywords: anthelmintic, development, helminths, mechanism, resistance, antiemetics, nausea, vomiting, mental illness.

Introduction. Helminths are a class of worms that pose a serious threat to animal health all over the world. Although managing domestic animal pastures may lessen the effects of parasites, these methods are insufficient to eradicate them. The use of pharmaceutical anthelmintics, which can account for the single biggest portion of animal health spending in many nations, has been the mainstay of helminthiasis control. Since there are currently no antiparasitic vaccinations, anthelmintic medications will likely continue to be the mainstay of treatment for veterinary helminth infections. Because of the anthelmintics' exceptional efficacy (more than 95% parasite elimination), broad spectrum nature, reasonable prices, and overall good safety margin, chemical control of parasites in animals has been incredibly successful during the past 50 years. Unfortunately, the extensive use of anthelmintic medications has resulted in a significant and alarming rise in anthelmintic resistance (AR), primarily of the gastrointestinal nematodes of cattle, sheep, goats, and horses [1-5]. Globally, the growing prevalence of AR in livestock

parasites is endangering animal health and productivity. The three anthelmintic groups that are currently most frequently utilized in small ruminants are cholinergic agonists (particularly levamisole; LEV), macrocyclic lactones (MLs), and benzimidazoles (BZs). AR has been documented in every anthelmintic class. It appears that resistance to an anthelmintic medication develops less than ten years after it is first introduced. The host, the parasite, the type of anthelmintic and how it is used, animal care, and environmental factors all have an impact on the complex process of AR development [6-11]. This makes it more difficult to design preventative and controlling methods, which may differ depending on the animal production systems. The development of AR is influenced by a number of factors, including the difficulties of developing new anthelmintics and the difficulty of turning resistant strains into susceptible ones. Effective alternative treatments to control the helminth infection have not yet been found, despite the fact that AR is occasionally on the rise and has become a significant concern as a result of the extensive use of anthelmintics. Therefore, it is crucial to regularly detect AR and comprehend the mechanisms and risk factors of anthelmintic resistance in order to restrict the spread of resistant parasites. Therefore, this review's primary goal is to draw attention to AR and its risk factors, mechanisms of development, detection techniques, and tactics for delaying AR's onset [12-15]. What can we do to address the scarcity of novel compounds? In preparation for the 27th International conference for the World Association for Veterinary Parasitology (WAAVP), an expert group at the 8th Consortium addressing Anthelmintic Resistance and Susceptibility (CARS) met on July 6, 2019 in Madison, Wisconsin, USA. Here, we provide a summary of these talks in the framework of the entire process of anthelmintic discovery and development, highlighting particular difficulties facing anthelmintics as well as chances to further research into the twenty-first century [16-19].

The main purpose of this presented analytical manuscript is to provide a brief analysis based on many years of scientific research on the classification of anthelmintic agents, indications for their use and disadvantages associated with their use.

The Mechanism of Anthelmintic Resistance. Anthelmintic Resistance Definition. In a parasite population that was previously susceptible to the same anthelmintic, AR is a heritable loss of anthelmintic sensitivity. When a greater percentage of the parasite individuals in a population are able to become less sensitive to anthelmintic doses than in a typical population of the same species, and when AR is passed down from generation to generation, it is thought to be present. AR comes in three varieties: multiple resistance, side resistance, and cross resistance. The first kind of resistance is called cross resistance, which occurs when a parasite strain can withstand therapeutic dosages of anthelmintics that are chemically unrelated or have different mechanisms of action [1,2,8,11]. Side resistance is a circumstance when resistance to an anthelmintic is caused by selection by another anthelmintic with a similar mechanism of action. It is the second form of resistance. One example of side resistance is resistance to anthelmintics that contain benzimidazoles. Levomimesole-resistant strains have been known to develop side resistance to morantel. The third type of anthelmintic resistance, referred to as multiple resistance, is the development of resistance to two or more anthelmintic agents with similar or different mechanisms of action due to either selection by each group separately or via side resistance [5-11].

The discovery and development of anthelmintics. Anthelmintic discovery and development are influenced by a wide range of factors, including procedures, obstacles, and drives. To improve potency, safety, pharmacokinetics, pharmacodynamics, and formulation, a chemical (or class) will usually go through multiple rounds of optimization. Regulatory standards require that the production process be created, cost-effectively optimized, and strictly regulated. Lastly, a medication needs to clear the regulatory requirements for both registration and continuous pharmacovigilance. Here, we address a few of the particular difficulties in anthelmintic discovery brought up throughout the CARS discussion [4-7].

Anthelmintic screening techniques. The best screening methods are still being debated in the field of anthelmintic discovery. Historically, anthelmintic discovery has been empirical, utilizing phenotypic whole organism assays with living parasites for large-scale screening. Lethality, larval development, and motility are among the assay readouts. This strategy has the benefit of target-blind tests, which can reveal new classes of compounds that a single target strategy could overlook. However, whole organism screening is frequently, but not always, low-throughput, resource-intensive, expensive, and necessitates specialized training, which is one of the main obstacles in anthelmintic discovery. Parasitic helminths must, by necessity, transit through a host, be kept in vivo, and then be isolated for analysis. As a result, obtaining the pertinent species or life stages could be challenging or impossible [7-12]. Because bacteria can be cultivated, maintained, and tested considerably more quickly than antibiotics, this significantly increases the expenses of anthelmintic discovery. Only a few effective rodent models are available to lower the expenses of ruminant parasites, which are very expensive. Another layer of complexity is that whole organism in vitro screens are not always indicative of clinical success, as history has taught us. For instance, the main medications used to prevent diseases brought on by the canine heartworm Dirofilaria immitis are macrocyclic lactones, or MLs. It has yet to be shown, but recent research suggests that the host's immune system and the host-parasite interaction may be important factors. This may be connected to how MLs affect the release of immune modulatory chemicals. Therefore, it is evident that no one method works for all parasites or all research objectives. In the end, we support more investigation into the basic biology of parasites, as this can guide the creation of models and assays to create more predictive tests for the detection and advancement of improved anthelmintics [9-14].

The difficulties of developing medication candidates preclinically. Effectiveness in vitro is just the first step; in order to move on to clinical development, a chemical must also exhibit suitable safety, stability, solubility, favorable pharmacokinetics and dynamics, and in vivo efficacy. Anthelmintics pose particular difficulties in each of these domains. Any drug discovery program must prioritize safety because any chemical could have negative consequences on a patient, both on and off target. Since parasites and their hosts are eukaryotic, they are more difficult to select for and keep safe from than bacteria, unlike antibiotics. Early in the discovery phase, counter-screening for undesirable side effects and undesired modes of action can and should be incorporated to help find inappropriate compounds long before they are given to an animal [1,2,3,7,9]. Naturally, this does not take into consideration circumstances in which intestinal reabsorption of medications eliminated through the bile may provide benefits for allowing a lower dosage of medication. Furthermore, it is unknown if a treatment for blood-feeding nematodes (such hookworm species) requires therapeutic blood levels to be effective. Furthermore, the need for a broad-spectrum anthelmintic may outweigh this benefit because many worms are present in organs other than the gastrointestinal system. Although there are formulation and delivery technologies to address these problems, they might not be financially viable for every indication and target species [5-9].

Regulatory obstacles to human and animal health. A novel anthelmintic medication must ultimately clear regulatory requirements for manufacture, safety, and effectiveness. According to standards from the Veterinary International Committee on Harmonization (VICH), anthelmintics must be as effective as 90% in contrast to other indication areas. For parasites like D. immitis or Echinococcus granulosus, the efficacy may need to reach 100%. When there is no other effective treatment for the stated parasites, effectiveness below 90% can be sufficient. Due to ecotoxicity and persistence in soil/sediment, which presents an additional challenge for livestock anthelmintics, the risk is thought to be much higher for livestock on pastures. Pharmaceuticals for humans and animals must be manufactured safely, user safety must be prioritized, and occupational exposure levels must be established after toxicological analyses. Lastly, the Chemistry, manufacture, and Controls (CMC) standards, which guarantee the uniformity and caliber of medication manufacture, are among the most difficult parts of the drug approval process [14-20].

Nature-inspired: Using natural materials to create novel anthelmintics. Given the difficulties, where might we search for novel anthelmintics? At CARS, we talked a lot on the discovery of natural product anthelmintics. As demonstrated by the discovery and development of avermectins, which were first discovered from the bacteria Streptomyces avermitilis in the 1970s, nature has already shown itself to be a useful resource for anthelmintic discovery. Millions of lives were saved when the macrocyclic lactone class, which became the most common class of anthelmintics, was later developed, revolutionizing both animal and human health. It is crucial to remember that effective natural product medications are mostly single components that have been extracted from a natural source; the entire plant, fungus, or bacteria is not necessary. Mixtures of natural products are inappropriate for the highly controlled medication production process, which has very severe quality assurance standards (CMC), because of the very variable nature of natural product development [3-8]. For example, plant genetics, the environment (rainfall, soil, temperature, pests, pesticides, and harvest time), and a variety of other factors can all have a significant impact on the production of compounds in plants. This can lead to varying amounts of active compounds as well as impurities. To address the observed lack of follow-up, we suggest improved communication and expectation management on the drug development process and natural product discovery, especially with reference to regulatory requirements. However, there is hope that the next ivermectin may be on the horizon due to the discovery of other anthelmintic chemicals from a wide range of plants and even more odd natural resources, such the venoms of funnel-web spiders and marine species [6-13].

Discussion. One of the main issues facing veterinary and human medicine is the control of helminth parasites. Anthelmintics are frequently used for prophylaxis and treatment when there are no effective vaccinations or proper hygiene. The demand for new classes of anthelmintics is driven by worries about side effects, lack of efficacy, drug resistance, and cost-effectiveness. Despite this need, no new anthelmintic classes have been licensed for use in humans, and only three new medication classes have made it to the animal market since 2000. How come anthelmintics are so hard to find? What obstacles stand in the way of discovering anthelmintics, and what new avenues for research can help overcome them? At the 8th Consortium for Anthelmintic Resistance and Susceptibility (CARS) in Wisconsin, USA, in 2019, this was the topic of a discussion session. Here, we highlight the difficulties specific to antiparasitic drug discovery and present the group's findings in the larger framework of the human and veterinary anthelmintic discovery pipeline. We discuss the reasons behind the scarcity of new anthelmintic development. We also go over possible avenues for medication development in the twenty-first century [1-7]. Since anthelmintic resistance promotes additional anthelmintic discovery, it served as the foundation for our discovery discussions. We have at least some partial misconceptions about the problem of anthelmintic resistance, according to our discussion group. In some parasites and geographical areas, such as Australian cattle industry, anthelmintic resistance is evidently a serious issue. To address this, there has to be a strong push for anthelmintic management and more funding for anthelmintic research. Along with soil-transmitted helminths, food-borne trematode infections are becoming more well recognized, and there are worries about the emergence of triclabendazole resistance [8,9,12,13,14]. One important way to get around this current resistance would be to find new classes and mechanisms of action. To guarantee the long-term viability of the new anthelmintic class, we must carefully manage and keep an eye out for the formation of resistance when introducing any fresh anthelmintic. To guarantee that owners and producers are properly informed about proper usage, industry, academics, governments, regulatory bodies, and clinicians must work together. This is an opportunity to fortify our relationships across all of these domains. We must look for and use new opportunities and technology to address the difficulties in the discovery of anthelmintic drugs. Concerns regarding the recruitment and retention of skilled scientists in parasitology research were raised by the discussion group's identification of the primary obstacle as the absence of financing for basic helminth research and anthelmintic discoveries. One of the main reasons for the lack of

funding was the low awareness of helminth illnesses, one of the neglected diseases [15-20]. The development of AR, a complex process influenced by the treated animal, the parasite, the kind of anthelmintic, and its use, is a result of the extensive use of anthelmintics to control helminths in cattle. Anthelmintic misuse, including underdosing, treating all animals on the same farm at the same time, administering the same anthelmintic repeatedly, using subpar quality, and using anthelmintic frequently, are major factors in the development of AR. The primary mechanisms of anthelmintic resistance include upregulation of cellular efflux mechanisms, increased drug metabolism, altered drug receptor sites that decrease drug binding or the functional effects of drug binding, and decreased drug receptor abundance due to decreased expression within the parasite [5-12].

Conclusions. In the CARS discussion group, the value of teamwork was underlined. The committee included individuals from academia, business, and a range of career phases and areas of expertise. The ensuing interactions between highly skilled senior researchers from many disciplines and professions and imaginative and passionate young researchers who were acquainted with cutting-edge scientific and communications technologies were beneficial for fostering fresh concepts and teamwork. Similar breakout conversations might be incorporated into future conferences to help foster these relationships. Because of the nature of anthelmintic discovery, cooperation and a variety of skills are needed, and it takes even more teamwork to ensure that novel anthelmintics are used responsibly. To increase our capacity for anthelmintic discovery into the twenty-first century, it will be essential to provide possibilities for the formation and maintenance of solid cross-disciplinary partnerships.

The primary mechanisms of anthelmintic resistance include upregulation of cellular efflux mechanisms, increased drug metabolism, altered drug receptor sites that decrease drug binding or the functional effects of drug binding, and decreased drug receptor abundance due to decreased expression within the parasite. There are currently no other efficient methods for controlling parasitic helminths outside the use of anthelmintics. Furthermore, the process of creating novel anthelmintics to treat AR is costly and time-consuming. Therefore, it is essential to use the current anthelmintics in a way that reduces the impact of AR, such as by using them appropriately and in combination and by lowering reliance on them. It's also critical to regularly detect and track the growth of AR.

References.

1. Fissiha W, Kinde MZ. Anthelmintic Resistance and Its Mechanism: A Review. Infect Drug Resist. 2021 Dec 15;14:5403-5410. doi: 10.2147/IDR.S332378.
2. Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr. 2020 Apr;43(2):49-56. doi: 10.18773/austprescr.2020.011.
3. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR., Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014 Jan;118(1):85-113.
4. Abdelsayed GG. Management of radiation-induced nausea and vomiting. Exp Hematol. 2007 Apr;35(4 Suppl 1):34-6.
5. Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician. 2015 Mar 01;91(5):293-6.
6. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012 Sep 05;104(17):1280-92.

7. Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf. 2010 Jan;5(1):105-11.
8. McParlin C, O'Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, Bradley J, Muirhead CR, Nelson-Piercy C, Newbury-Birch D, Norman J, Shaw C, Simpson E, Swallow B, Yates L, Vale L. Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. JAMA. 2016 Oct 04;316(13):1392-1401.
9. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev 2011;(9):CD005506. 10.1002/14651858.CD005506.pub5
10. Fallon R, Boulger S, Fraser C, Moriarty K. Recommended drug options for nausea and vomiting. Prescriber 2010;21:18-33. 10.1002/psb.590
11. *Murnion B. Medicinal cannabis. Aust Prescr 2015;38:212-5. 10.18773/austprescr.2015.072*
12. Hendren G, Aponte-Feliciano A, Kovac A. Safety and efficacy of commonly used antiemetics. Expert Opin Drug Metab Toxicol 2015;11:1753-67. 10.1517/17425255.2015.1080688
13. *Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med 2012;1:137-42. 10.3978/j.issn.2224-5820.2012.07.09*
14. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-42. 10.1056/NEJMoa1515725
15. *Tageja N, Groninger H. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 2016;92:34-40. 10.1136/postgradmedj-2014-132969*
16. Royal Children's Hospital Melbourne. Clinical Practice Guidelines: Gastroenteritis. Updated 2015 Aug. www.rch.org.au/clinicalguide/guideline_index/ Gastroenteritis
17. *Tfelt-Hansen PC. Delayed absorption of many (paracetamol, aspirin, other NSAIDs and zolmitriptan) but not all (sumatriptan, rizatriptan) drugs during migraine attacks and most likely normal gastric emptying outside attacks. A review. Cephalalgia 2017;37:892-901. 10.1177/0333102416644745*
18. *Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA 2018;320:2429-37. 10.1001/jama.2018.18307*
19. Dulal S, Paudel BD, Neupane P, Shah A, Acharya B, Poudyal BS. Randomized phase II trial to compare the efficacy of haloperidol and olanzapine in the control of chemotherapy-induced nausea and vomiting in Nepal J Glob Oncol 2019;5:1-6. https://dx.doi.org/10.1200%2FJGO.18.00245
20. Nixon SA, Welz C, Woods DJ, Costa-Junior L, Zamanian M, Martin RJ. Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics. Int J Parasitol Drugs Drug Resist. 2020 Dec;14:8-16. doi: 10.1016/j.ijpddr.2020.07.001.